| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
70,010,000 |
| Market
Cap: |
578.28(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.18 - $12.9 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Zymeworks is a clinical-stage biopharmaceutical company focused on the development of multifunctional biotherapeutics. Co.'s primary product candidate, zanidatamab, is a bispecific (dual-targeting) antibody that targets two domains of the human epidermal growth factor receptor 2. Co.'s second product candidate, ZW49, combines the design of zanidatamab with its ZymeLink antibody-drug conjugate platform, comprised of its proprietary cytotoxin (cancer cell-killing compound) and cleavable linker. Co. is also developing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
2,475 |
| Total Sell Value |
$0 |
$0 |
$0 |
$20,045 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Josephson Neil |
Chief Medical Officer |
• – – |
2022-11-10 |
4 |
AS |
$8.10 |
$20,045 |
D/D |
(2,475) |
14,449 |
|
- |
|
| Josephson Neil |
Chief Medical Officer |
• – – |
2022-11-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,885 |
16,924 |
|
- |
|
| Josephson Neil |
Chief Medical Officer |
• – – |
2022-07-05 |
4 |
A |
$4.51 |
$6,878 |
D/D |
1,525 |
11,039 |
|
- |
|
| Klompas Neil A |
Chief Operating Officer |
• – – |
2022-07-05 |
4 |
A |
$4.51 |
$6,878 |
D/D |
1,525 |
14,801 |
|
- |
|
| Josephson Neil |
Chief Medical Officer |
• – – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,395 |
9,514 |
|
- |
|
| Klompas Neil A |
Chief Operating Officer |
• – – |
2022-03-10 |
4 |
AS |
$6.88 |
$20,496 |
D/D |
(2,979) |
13,276 |
|
-11% |
|
| Klompas Neil A |
Chief Operating Officer |
• – – |
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,208 |
16,255 |
|
- |
|
| Astle Christopher |
SVP & Chief Financial OfficerO |
• – – |
2022-02-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
670 |
|
-21% |
|
| Josephson Neil |
Chief Medical Officer |
• – – |
2022-01-07 |
4 |
B |
$14.27 |
$71,386 |
D/D |
5,000 |
7,119 |
2.74 |
-63% |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2022-01-07 |
4 |
A |
$13.94 |
$1,032 |
D/D |
74 |
36,407 |
|
- |
|
| Josephson Neil |
Chief Medical Officer |
• – – |
2022-01-07 |
4 |
A |
$13.94 |
$906 |
D/D |
65 |
2,119 |
|
- |
|
| Klompas Neil A |
Chief Operating Officer & CFO |
• – – |
2022-01-07 |
4 |
A |
$13.94 |
$3,861 |
D/D |
277 |
11,047 |
|
- |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2021-08-31 |
4 |
OE |
$15.00 |
$73,500 |
D/D |
4,900 |
36,333 |
|
- |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2021-07-16 |
4 |
AS |
$36.00 |
$1,482,876 |
D/D |
(41,191) |
260,325 |
|
-44% |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2021-07-16 |
4 |
OE |
$4.26 |
$175,651 |
D/D |
41,191 |
301,516 |
|
- |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2021-07-15 |
4 |
AS |
$36.00 |
$136,800 |
D/D |
(3,800) |
260,325 |
|
-44% |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2021-07-15 |
4 |
OE |
$4.27 |
$16,231 |
D/D |
3,800 |
264,125 |
|
- |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2021-07-12 |
4 |
AS |
$36.12 |
$457,635 |
D/D |
(12,669) |
260,325 |
|
-44% |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2021-07-12 |
4 |
OE |
$4.31 |
$54,555 |
D/D |
12,669 |
272,994 |
|
- |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2021-07-06 |
4 |
A |
$29.49 |
$13,388 |
D/D |
454 |
31,433 |
|
- |
|
| Odriscoll Kathryn |
Chief People Officer |
• – – |
2021-07-06 |
4 |
A |
$29.49 |
$15,040 |
D/D |
510 |
6,350 |
|
- |
|
| Josephson Neil |
Interim Chief Medical Officer |
• – – |
2021-07-06 |
4 |
A |
$29.49 |
$13,595 |
D/D |
461 |
2,054 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2021-07-06 |
4 |
A |
$29.49 |
$8,818 |
D/D |
299 |
10,770 |
|
- |
|
| Priour James |
Chief Commercial Officer |
• – – |
2021-07-06 |
4 |
A |
$29.49 |
$15,040 |
D/D |
510 |
2,513 |
|
- |
|
| Priour James |
Chief Commercial Officer |
• – – |
2021-04-13 |
4 |
AS |
$27.93 |
$26,533 |
D/D |
(950) |
2,003 |
|
13% |
|
97 Records found
|
|
Page 1 of 4 |
|
|
0.15 (1.85%) 
